

RenalGuard® is indicated for temporary replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume.

Features

- Closed loop fluid management system
- High fluid volume pump
- High accuracy, dual weight measuring system
- Motion-detected artifact reduction
- Proprietary disposables
 - Single-use intravenous set
 - Urine collection system that interfaces with a standard Foley catheter
- Real-time display of urine and hydration fluid volumes and urine rate
- User-selected fluid bolus administration
- Automatic battery back-up
- Automatic priming of the infusion set
- Timely alerts to drain urine bag or to replace hydration fluid bag
- Safety features such as automatic air detection intravenous occlusions


Specifications

- Dimensions: 36×18×23 cm (H × W × D)
- Weight: 4.1 kg
- Mains Voltage: 100–240 VAC, 60/50 Hz Power: 50 VA
- Flow Rates: KVO rate 10–100 ml/hr
- Normal Operating Range: 10–3000 ml/hr
- Maximum Flow Rate: 6000 ml/hr up to 3 mins

RenalGuard® is CE-marked for the intended use of temporary (up to 14 days) replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. The RenalGuard System is not intended for infusion of blood, blood components, medications, or nutritional fluids. All treatments administered via The RenalGuard System must be prescribed by a physician. RenalGuard Solutions, Inc. reserves the right to modify the specifications and features described herein, or discontinue manufacture of the product described at any time without prior notice or obligation.

RenalGuard, RenalGuard Therapy and the RenalGuard Logo are trademarks of PLC Medical Systems, Inc., a subsidiary of RenalGuard Solutions. RenalGuard Solutions and the RenalGuard Solutions logo are trademarks of

RenalGuard Solutions.
459 Fortune Boulevard, Milford, MA 01757
Tel: (508) 541-8800 Fax: (508) 541-7980
www.RenalGuard.com info@RenalGuard.com
Limited by US Law to Investigational Use only in the US
BR00CSRevA



RenalGuard Therapy® For Cardiac Surgery



Personalized, Matched Hydration Therapy
Preventing AKI in High-Risk Cardiac Surgery Patients



RenalGuard® a new, clinically validated approach for preventing Cardiac Surgery Associated AKI with personalized matched hydration therapy.¹

- Creates and maintains a high urine output
- Maintains balanced hydration by matching fluid input to urine output in real time
- Automatic control reduces the risk of over and under-hydration

RenalGuard® simplifies AKI management for high-risk cardiac surgery patients


- Easy to set up and operate
- Fits into normal cardiac surgery work-flow
- Therapy begins 30 minutes before procedure, continues during, and completes 4 hours afterwards.
- Nurse-operated during the procedure, allowing the physician to focus on surgery



Standard of Care

- **Limited efficacy to prevent AKI**
With high clinical burden and associated costs
- **Passive Monitoring of Urine Output**
Delays diagnosis of AKI progression
- **Adverse Effects include Pulmonary Edema**
Due to risk of manual over hydration

52% Reduction in AKI



KIDNEY Study: The validation trial demonstrated a 52% reduction in AKI in cardiac surgery patients when treated with **RenalGuard®** vs the standard of care.¹